Remission of myasthenia gravis following infection with SARS-CoV-2: A case report
Abstract
This case report describes an unprecedented remission of ocular Myasthenia Gravis (MG) in a 3-year-old girl following a SARS-CoV-2 infection. Both MG and SARS-CoV-2 influence the cholinergic system, and this case underscores the importance of considering multiple factors in autoimmune disorders and the potential impact of viral infections on their course. The patient initially presented with ptosis and limited eye movement. Her diagnosis of seronegative MG was confirmed with abnormal visual evoked potentials and positive response to pyridostigmine. Her ptosis and limited extraocular muscle movement were intermittent until 2 years later when she tested positive for SARS-CoV-2 for which no antiviral medication was taken. Unexpectedly, her MG symptoms rapidly improved postinfection, leading to the cessation of pyridostigmine. This case highlights the complex interplay between MG, viral infections, and the influence of anti-acetylcholine receptor antibodies, second-hand smoke, and natural nicotinic agonists from the use of pyridostigmine on the cholinergic system.
Related
- Probable Seronegative Myasthenia Gravis With Initially Negative Diagnostic Testing: A Case Report
- Anesthetic Management of a Patient With Myasthenia Gravis Undergoing Thoracoscopic Thymectomy: A Case Report and Literature Review
- Suspected Bulbar-Predominant Myasthenia Gravis Exacerbation in an Older Adult With Respiratory Deterioration and Silent Aspiration: A Case Report
- Ocular Myasthenia Gravis Unmasking Molecularly High-Risk but Clinically Indolent Chronic Lymphocytic Leukemia: A Case Report
- Confirmed Myocarditis-Myositis Overlap Without Myasthenia Gravis: Evaluating for Triple M Syndrome Following Combined Enfortumab Vedotin and Pembrolizumab Therapy.
BibTeX
@article{lin2026remission,
title = {{Remission of myasthenia gravis following infection with SARS-CoV-2: A case report}},
author = {Che-Yu Lin and Shannon Su and Ann Yi-Chiun Chuang},
journal = {Taiwan Journal of Ophthalmology},
year = {2026},
month = jul,
doi = {10.4103/tjo.tjo-d-24-00087},
url = {https://doi.org/10.4103/tjo.tjo-d-24-00087},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Remission of myasthenia gravis following infection with SARS-CoV-2: A case report
AU - Che-Yu Lin
AU - Shannon Su
AU - Ann Yi-Chiun Chuang
PY - 2026
DA - 2026/07/01
JO - Taiwan Journal of Ophthalmology
DO - 10.4103/tjo.tjo-d-24-00087
UR - https://doi.org/10.4103/tjo.tjo-d-24-00087
AB - This case report describes an unprecedented remission of ocular Myasthenia Gravis (MG) in a 3-year-old girl following a SARS-CoV-2 infection. Both MG and SARS-CoV-2 influence the cholinergic system, and this case underscores the importance of considering multiple factors in autoimmune disorders and the potential impact of viral infections on their course. The patient initially presented with ptosis and limited eye movement. Her diagnosis of seronegative MG was confirmed with abnormal visual evoked potentials and positive response to pyridostigmine. Her ptosis and limited extraocular muscle movement were intermittent until 2 years later when she tested positive for SARS-CoV-2 for which no antiviral medication was taken. Unexpectedly, her MG symptoms rapidly improved postinfection, leading to the cessation of pyridostigmine. This case highlights the complex interplay between MG, viral infections, and the influence of anti-acetylcholine receptor antibodies, second-hand smoke, and natural nicotinic agonists from the use of pyridostigmine on the cholinergic system.
SN - 2211-5056
SN - 2211-5072
ER -